GlassScriptPhysician profile
Rishika Kaundal
NPI 1902192370
$9,705.14
in general payments reported to CMS, 2019-2025
56 companies · $1,418 in 2025
The $1,418 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $774 · 2020: $891 · 2021: $1,738 · 2022: $1,336 · 2023: $1,260 · 2024: $2,289 · 2025: $1,418.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,967.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,966.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,391.33 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,244.61 | 2019-2025 | |
| Pfizer INC. | $858.77 | 2019-2025 | |
| Lilly USA, LLC | $758.99 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $594.72 | 2019-2025 | Xifaxan, Trulance |
| Amgen INC. | $575.80 | 2019-2024 | Repatha, Otezla, Prolia |
| Astrazeneca Pharmaceuticals LP | $544.77 | 2020-2025 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $356.51 | 2019-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $262.38 | 2021-2025 | Jardiance |
| Allergan, INC. | $257.77 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $173.37 | 2021 | |
| Dexcom, INC. | $160.28 | 2021-2025 | Dexcom G6 Transmitter |
| Daiichi Sankyo INC. | $159.60 | 2021-2024 | Injectafer |
| Teva Pharmaceuticals USA, INC. | $140.33 | 2019-2023 | Austedo |
| Phathom Pharmaceuticals, INC. | $140.30 | 2024-2025 | Voquezna |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rishika Kaundal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.